BullFrog AI Unveils Whitepaper Showcasing AI Platform for Drug Discovery
BullFrog AI Holdings Inc. has published a whitepaper detailing its AI-driven technologies in bioinformatics, focusing on the BullFrog Data Networks® and bfLEAP® platform. The whitepaper highlights advancements in drug discovery, including improved target identification, biomarker discovery, and patient stratification, using methods developed at Johns Hopkins Applied Physics Laboratory. The document is available for download.
BullFrog AI Holdings Inc. has announced the publication of a new whitepaper detailing the scientific advances of its AI-driven technologies in bioinformatics. The company’s research highlights how its BullFrog Data Networks® and bfLEAP® platform address major challenges in drug discovery by transforming complex biological data into actionable insights. The whitepaper outlines how BullFrog AI’s causal inference and probabilistic validation methods, originally developed at the Johns Hopkins Applied Physics Laboratory, improve the reliability of target identification, biomarker discovery, and patient stratification. These results have already been published in the new whitepaper, which is available for download. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BullFrog AI Holdings Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
